Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis

BACKGROUND: The WHO Strategic Advisory Group of Experts recommended that an extended interval of 3–5 years between the two doses of the human papillomavirus (HPV) vaccine could be considered to alleviate vaccine supply shortages. However, three concerns have limited the introduction of extended sche...

Descripción completa

Detalles Bibliográficos
Autores principales: Bénard, Élodie, Drolet, Mélanie, Laprise, Jean-François, Jit, Mark, Prem, Kiesha, Boily, Marie-Claude, Brisson, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764452/
https://www.ncbi.nlm.nih.gov/pubmed/36521952
http://dx.doi.org/10.1016/S2214-109X(22)00475-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764452/
https://www.ncbi.nlm.nih.gov/pubmed/36521952
http://dx.doi.org/10.1016/S2214-109X(22)00475-2

Ejemplares similares